Loading...
Please wait, while we are loading the content...
Similar Documents
Direct-acting Antivirals and Host-targeting Agents against the Hepatitis A Virus
| Content Provider | Semantic Scholar |
|---|---|
| Author | Kanda, Tatsuo Nakamoto, Shingo Wu, Shuang Nakamura, Masato Jiang, Xia Haga, Yuki Sasaki, Reina Yokosuka, Osamu |
| Copyright Year | 2015 |
| Abstract | Hepatitis A virus (HAV) infection is a major cause of acute hepatitis and occasionally leads to acute liver failure in both developing and developed countries. Although effective vaccines for HAV are available, the development of new antivirals against HAV may be important for the control of HAV infection in developed countries where no universal vaccination program against HAV exists, such as Japan. There are two forms of antiviral agents against HAV: direct-acting antivirals (DAAs) and host-targeting agents (HTAs). Studies using small interfering ribonucleic acid (siRNA) have suggested that the HAV internal ribosomal entry site (IRES) is an attractive target for the control of HAV replication and infection. Among the HTAs, amantadine and interferon-lambda 1 (IL-29) inhibit HAV IRES-mediated translation and HAV replication. Janus kinase (JAK) inhibitors inhibit La protein expression, HAV IRES activity, and HAV replication. Based on this review, both DAAs and HTAs may be needed to control effectively HAV infection, and their use should continue to be explored. |
| Starting Page | 205 |
| Ending Page | 210 |
| Page Count | 6 |
| File Format | PDF HTM / HTML |
| DOI | 10.14218/JCTH.2015.00016 |
| Alternate Webpage(s) | http://publine.xiahepublishing.com/journals/10.14218/JCTH.2015.00016.pdf |
| PubMed reference number | 26623267 |
| Alternate Webpage(s) | https://doi.org/10.14218/JCTH.2015.00016 |
| Journal | Medline |
| Volume Number | 3 |
| Journal | Journal of clinical and translational hepatology |
| Language | English |
| Access Restriction | Open |
| Content Type | Text |
| Resource Type | Article |
